DOCSLIB.ORG

Sokestrategi PICO 1.4 Dokument

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sokestrategi PICO 1.4 Dokument Acetylsalisylsyre, clopidogrel og antikoagulasjon – PICO 1.4 Kontaktperson: Liv Hege Kateraas og Bent Indredavik Søk: Marita Heintz Kommentar: Søk etter systematiske oversikter Tidsbruk: 25 timer Pico-skjema: Spørsmålet i PICO format Hva handler spørsmålet om? Comparison Populasjon Outcome(s) Intervensjon (tiltak) (sammenligning/ (pasient) (utfall/effekt) kontroll) Har pasienter med TIA/ TIA/ akutt hjerneinfarkt Tillegg av clopidogrel Hjerneinfarkt / pasienter som bruker eller antikoagulasjon vaskulære aktutt hjerneinfarkt acetylsalicylsyre hendelser / død som bruker acetylsalisylsyre, effekt av clopidogrel eller antikoagulasjon i tillegg? Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Dato: 27.05.2016 Antall treff: 191 (186 etter sletting av interne dubletter) stroke/ or cerebral infarction/ or dementia, multi-infarct/ or infarction, anterior cerebral artery/ or infarction, middle cerebral artery/ or infarction, posterior cerebral artery/ or stroke, lacunar/ or brain 1 ischemia/ or carotid artery, internal, dissection/ or carotid artery thrombosis/ or "intracranial 136566 embolism and thrombosis"/ or intracranial embolism/ or intracranial thrombosis/ or vertebral artery dissection/ 2 (stroke or cerebrovasc* or cerebral vasc*).tw. 212662 ((brain* or cerebr* or cerebell* or vertebrobasilar or hemispher* or intracran* or intracerebral or MCA 3 or anterior circulation or posterior circulation or basal ganglia or penumbra) adj5 (isch?emi* or 84829 infarct* or thrombo* or emboli*)).tw. 4 Ischemic Attack, Transient/ 18590 (TIA or TIAs or ((ischemic or ischaemic) adj (attack? or seizure?)) or (transient adj (brainstem or 5 16514 brain or "brain stem" or cerebral) adj (ischemia? or ischaemia?))).tw. 6 or/1-5 304555 7 Aspirin/ or Aspirin, Dipyridamole Drug Combination/ 40351 (acetylsalicyl or acetylsalicylate or acetysal or acidulatum or "acidum acetylosalicylicum" or "acidum 8 acetylsalicylicum" or albyle or "albyl e" or "alka seltzer" or asasantin or "asasantine lp" or asatard or 58721 asawin or aspirin or aspirina).mp. (("ortho acetoxybenzoic" or "ortho acetyloxybenzoic" or acetylsalicylic or acetylsalycic or 9 acetylsalycylic or acetosalicylic or "2 acetoxybenzoic" or "acetyl salicylic" or "acetylic salicylic" or 9560 acetylosalicylic or acetylsalicyclic) adj1 acid).mp. 10 or/7-9 61478 11 Ticlopidine/aa [Analogs & Derivatives] 7203 (clopidogrel* or Iscover or Plavix or "Platelet Aggregation Inhibitors" or "Purinergic P2Y Receptor Antagonists" or clopilet or grepid or zopya or zylagren or zyllt or duocover or duoplavin or "SC 12 33931 25989C" or SC25989C or "SC 25990C" or SC25990C or "SR 25989*" or SR25989* or "SR 25990C" or SR25990C or "PCR 4099" or PCR4099).mp. 13 exp anticoagulants/ 192004 14 exp Blood Coagulation/ai, de [Antagonists & Inhibitors, Drug Effects] 17407 15 exp Blood Coagulation Factors/ai [Antagonists & Inhibitors] 14008 16 (anticoagul* or antithromb*).tw. 93566 17 exp antithrombins/ 17816 18 hirudin therapy/ 637 19 thrombin/ai [Antagonists & Inhibitors] 3500 (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or 20 flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or 9909 desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin or odiparcil).mp. (antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or ym 150 or ym150 or LY517717 or darexaban or 21 4851 edoxaban or SSR126517E or fidexaban or idrabiotaparinux or letaxaban or tanogitran or taxexaban).mp. 22 heparin/ 51329 23 exp heparin, low-molecular-weight/ 10694 24 heparinoids/ 921 (heparin* or lmwh* or enoxaparin* or glycosaminoglycan* or nadroparin* or mesoglycan* or 25 tedelparin* or certoparin or tinzaparin or parnaparin or dalteparin or reviparin or fraxiparin* or 132454 danaparoid or lomoparan or org 10172 or mesoglycan or pentosan polysul* or sp54 or sp-54 or cy222 or cy-222 or cy216 or cy-216 or dermatan sul* or heparan sul*).mp. 26 Factor Xa Inhibitors/ 2826 ((("direct thrombin" or "factor xa" or "factor 10a" or fXa or "autoprothrombin c" or thrombokinase or 27 6106 "activated factor X" or "factor 10") adj2 inhibit*) or xabans).mp. 28 exp Vitamin K/ai [Antagonists & Inhibitors] 1969 29 ("vitamin K antagonist*" or "vitamink antagonist*" or VKA or VKAs or "antivitamin K").tw. 3576 Warfarin/ or 4-hydroxycoumarins/ or acenocoumarol/ or coumarins/ or dicumarol/ or ethyl 30 32541 biscoumacetate/ or phenindione/ or phenprocoumon/ or coumafos/ (coumarin* or cumarin* or phenprocoum* or phenprocum* or dicoumar* or dicumar* or acenocoumar* or acenocumar* or fluindione or phenindione or clorindione or ethyl biscoumacetate or diphenadione or marevan or warfarin* or coumadin* or jantoven or lawarin or waran or warfant or 31 46091 adoisine or aldocumar or athrombin* k or carfin or coumafene or coumaphene or kumatox or panwarfarin or panwarfin or prothromadin or sofarin or tedicumar or tintorane or waran or warfilone or warnerin).mp. 32 (((new or novel) adj2 oral anticoagulant*) or NOAC).tw. 2110 33 Dabigatran/ or Rivaroxaban/ 2438 (dabigatran or "bibr 1048" or bibr1048 or pradax or pradaxa or prazaxa or rendix or "bibr 953" or bibr953 or rivaroxaban or xarelto or "BAY 59 7939" or "BAY 597939" or "BAY59 7939" or BAY597939 or apixaban or "bms 562247" or bms562247 or eliques or eliquis or edoxaban or lixiana 34 6391 or savaysa or "du 176" or "du 176b" or du176 or du176b or antistasin or betrixaban or "du 176b" or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or yagin or "ym 150" or ym150 or LY517717 or darexaban or SSR126517E).mp. 35 or/11-34 356193 36 6 and 10 and 35 5452 37 ((systematic* or literature) adj2 review*).mp. 197770 38 (metaanalys* or meta analys*).mp. or (meta analysis or review).pt. 2190404 39 37 or 38 2254220 40 36 and 39 1822 41 limit 40 to yr="2014 -Current" 191 Database: Embase 1974 to 2016 May 26 Dato: 27.05.2016 Antall treff: 247 (235 etter sletting av interne dubletter) cerebrovascular accident/ or brain infarction/ or multiinfarct dementia/ or cerebral artery disease/ or 1 lacunar stroke/ or brain ischemia/ or carotid artery injury/ or carotid artery thrombosis/ or brain 261586 embolism/ or occlusive cerebrovascular disease/ or artery dissection/ 2 (stroke or cerebrovasc* or cerebral vasc*).tw. 310963 ((brain* or cerebr* or cerebell* or vertebrobasilar or hemispher* or intracran* or intracerebral or MCA 3 or anterior circulation or posterior circulation or basal ganglia or penumbra) adj5 (isch?emi* or infarct* 115416 or thrombo* or emboli*)).tw. 4 transient ischemic attack/ 29162 (TIA or TIAs or ((ischemic or ischaemic) adj (attack? or seizure?)) or (transient adj (brainstem or brain 5 26044 or "brain stem" or cerebral) adj (ischemia? or ischaemia?))).tw. 6 or/1-5 469116 7 acetylsalicylic acid/ or acetylsalicylic acid plus dipyridamole/ 177684 (acetylsalicyl or acetylsalicylate or acetysal or acidulatum or "acidum acetylosalicylicum" or "acidum 8 acetylsalicylicum" or albyle or "albyl e" or "alka seltzer" or asasantin or "asasantine lp" or asatard or 103758 asawin or aspirin or aspirina).mp. (("ortho acetoxybenzoic" or "ortho acetyloxybenzoic" or acetylsalicylic or acetylsalycic or 9 acetylsalycylic or acetosalicylic or "2 acetoxybenzoic" or "acetyl salicylic" or "acetylic salicylic" or 179662 acetylosalicylic or acetylsalicyclic) adj1 acid).mp. 10 or/7-9 187544 11 clopidogrel/ 44865 (clopidogrel* or Iscover or Plavix or "Platelet Aggregation Inhibitors" or "Purinergic P2Y Receptor Antagonists" or clopilet or grepid or zopya or zylagren or zyllt or duocover or duoplavin or "SC 12 46847 25989C" or SC25989C or "SC 25990C" or SC25990C or "SR 25989*" or SR25989* or "SR 25990C" or SR25990C or "PCR 4099" or PCR4099).mp. exp anticoagulant agent/ or anticoagulant therapy/ or exp thrombin inhibitor/ or exp blood clotting 13 571957 factor 10a inhibitor/ or 4 hydroxycoumarin/ or coumarin/ or coumarin derivative/ 14 (anticoagul* or antithromb*).tw. 132351 (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or 15 flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or 23701 desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin or odiparcil).mp. (antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or ym 150 or ym150 or LY517717 or darexaban or 16 14528 edoxaban or SSR126517E or fidexaban or idrabiotaparinux or letaxaban or tanogitran or taxexaban).mp. (heparin* or lmwh* or enoxaparin* or glycosaminoglycan* or nadroparin* or mesoglycan* or tedelparin* or certoparin or tinzaparin or parnaparin or dalteparin or reviparin or fraxiparin* or 17 230987 danaparoid or lomoparan or org 10172 or mesoglycan or pentosan polysul* or sp54 or sp-54 or cy222 or cy-222 or cy216 or cy-216 or dermatan sul* or heparan sul*).mp. ((("direct thrombin" or "factor xa" or "factor 10a" or fXa or "autoprothrombin c" or thrombokinase or 18 8494 "activated factor X" or "factor 10") adj2 inhibit*) or xabans).mp. 19 ("vitamin K antagonist*" or "vitamink antagonist*" or VKA or VKAs or "antivitamin K").tw. 6038 (coumarin* or cumarin* or phenprocoum* or phenprocum* or dicoumar* or dicumar* or acenocoumar* or acenocumar* or fluindione or phenindione or clorindione or ethyl biscoumacetate or diphenadione 20 or marevan or warfarin* or
Load more

Recommended publications
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Edward R. Kastenhuber1, Javier A. Jaimes2, Jared L. Johnson1, Marisa Mercadante1, Frauke Muecksch3, Yiska Weisblum3, Yaron Bram4, Robert E. Schwartz4,5, Gary R. Whittaker2 and Lewis C. Cantley1,* Affiliations 1. Meyer Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 2. Department of Microbiology and Immunology, Cornell University, Ithaca, New York, USA. 3. Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. 4. Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 5. Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY, USA. *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Coagulopathy is recognized as a significant aspect of morbidity in COVID-19 patients. The clotting cascade is propagated by a series of proteases, including factor Xa and thrombin. Other host proteases, including TMPRSS2, are recognized to be important for cleavage activation of SARS-CoV-2 spike to promote viral entry. Using biochemical and cell-based assays, we demonstrate that factor Xa and thrombin can also directly cleave SARS-CoV-2 spike, enhancing viral entry.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Heparin EDTA Patent Application Publication Feb
    US 20110027771 A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0027771 A1 Deng (43) Pub. Date: Feb. 3, 2011 (54) METHODS AND COMPOSITIONS FORCELL Publication Classification STABILIZATION (51) Int. Cl. (75)75) InventorInventor: tDavid Deng,eng, Mountain rView, V1ew,ar. CA C09KCI2N 5/073IS/00 (2006.01)(2010.01) C7H 2L/04 (2006.01) Correspondence Address: CI2O 1/02 (2006.01) WILSON, SONSINI, GOODRICH & ROSATI GOIN 33/48 (2006.01) 650 PAGE MILL ROAD CI2O I/68 (2006.01) PALO ALTO, CA 94304-1050 (US) CI2M I/24 (2006.01) rsr rr (52) U.S. Cl. ............ 435/2; 435/374; 252/397:536/23.1; (73) Assignee: Arts Health, Inc., San Carlos, 435/29: 436/63; 436/94; 435/6: 435/307.1 (21) Appl. No.: 12/847,876 (57) ABSTRACT Fragile cells have value for use in diagnosing many types of (22) Filed: Jul. 30, 2010 conditions. There is a need for compositions that stabilize fragile cells. The stabilization compositions of the provided Related U.S. Application Data inventionallow for the stabilization, enrichment, and analysis (60) Provisional application No. 61/230,638, filed on Jul. of fragile cells, including fetal cells, circulating tumor cells, 31, 2009. and stem cells. 14 w Heparin EDTA Patent Application Publication Feb. 3, 2011 Sheet 1 of 17 US 2011/0027771 A1 FIG. 1 Heparin EDTA Patent Application Publication Feb. 3, 2011 Sheet 2 of 17 US 2011/0027771 A1 FIG. 2 Cell Equivalent/10 ml blood P=0.282 (n=11) 1 hour 6 hours No Composition C Composition C Patent Application Publication Feb.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • 9719087.Pdf (3.190Mb)
    US009719087B2 a2) United States Patent (0) Patent No.: US 9,719,087 B2 Olson et al. (45) Date of Patent: *Aug. 1, 2017 (54) MICRO-RNA FAMILY THAT MODULATES A61LK 39/3955 (2013.01); AGLK 45/06 FIBROSIS AND USES THEREOF (2013.01); A6IL 31/08 (2013.01); AGIL 31/16 (2013.01); C12N 9/16 (2013.01); C12N (71) Applicant: THE BOARD OF REGENTS, THE 15/8509 (2013.01); AOIK 2207/30 (2013.01); UNIVERSITY OF TEXAS SYSTEM, AOIK 2217/052 (2013.01); AOLK 2217/075 Austin, TX (US) (2013.01); AOIK 2217/15 (2013.01); AOIK 2217/206 (2013.01); AOIK 2227/105 (72) Inventors: Erie N. Olson, Dallas, TX (US); Eva (2013.01); AOIK 2267/0375 (2013.01); AIL van Rooij, Utrecht (NL) 2300/258 (2013.01); A6IL 2300/45 (2013.01); : AOIL 2420/06 (2013.01); C12N 2310/113 (73) Assignee: THE BOARD OF REGENTS, THE (2013.01); CI2N 2310/141 (2013.01); CI2N UNIVERSITY OF TEXAS SYSTEM, 2310/315 (2013.01); C12N 2310/321 Austin, TX (US) (2013.01); C12N 2310/346 (2013.01); C12N (*) Notice: Subjectto any disclaimer, the termbe this (013.01ars orb01301CDN US.C.patent154(b)is extendedby 0 ordays.adjusted under 2320/32 (2013.01);4 . CI2N 2330/10yor(2013.01) (58) Field of Classification Search This patent is subject to a terminal dis- CPC vieceeceseeseeeeeeee C12N 15/113; C12N 2310/141 claimer. See application file for complete search history. — (21) Appl. No.: 14/592,699 (56) References Cited (22) Filed: Jan. 8, 2015 U.S. PATENT DOCUMENTS (65) Prior Publication Data 7,232,806 B2 6/2007 Tuschlet al.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]